Some aspects of this disclosure provide modified mRNA (modRNA) encoding retinaldehyde dehydrogenase (RALDH) enzyme, in addition to methods of synthesis, administration, use, and treatment. In some embodiments, the modRNA may be used in a vaccine to treat infections (e.g., mucosal infections) and/or cancers (e.g., mucosal cancers).

The invention provides American chestnut leaf compositions comprising oxalate oxidase. The compositions reduce oxalate levels in dietary sources of oxalate and are useful in reducing oxalate levels and reducing stone disease in patients. The invention provides methods of extracting and purifying oxalate oxidase from American chestnut leaf. The invention provides methods of extracting oxalate from biological samples.

Provided herein are microorganisms and methods for fermentative production of ß-ketoadipate from gaseous substrates such as carbon dioxide (CO.sub.2), carbon monoxide (CO), and/or hydrogen (H.sub.2). Additionally, the processes provided herein are methods for producing polymers containing ß-ketoadipate, that can potentially enable a circular economy by diverting waste, e.g., plastic waste.

A method of the bio-production of methionine and/or of its derivatives thereof from a reduced source of sulfur, such as MeSH or MeSNa including genetically modified yeasts, having an increased ability to produce methionine and/or its derivatives thereof, as compared to the parent yeasts.

Many biotechnologically relevant organisms cannot utilize cheap and abundant one carbon feedstocks, e.g. CO.sub.2, CO, formaldehyde, methanol, and methane, for growth and instead prefer complex feedstocks such as sugars. Disclosed herein is a system that enables organisms to consume one carbon molecules for growth and maintenance via a formyl-CoA elongation pathway. Utilization of one carbon feedstocks can replace the use of sugar as the primary means of cultivating organisms in biotechnological applications. This has the potential to be more cost effective and avoid the controversial use of food as feedstocks. Intermediates of the formyl-CoA elongation pathway may be also be converted to desired chemical products.

The present disclosure provides methods and compositions for producing artemisinic acid, dihydroartemisinic acid or artemisinin. In various aspects, the present disclosure provides enzymes, polynucleotides encoding said enzymes, and recombinant microbial host cells (or microbial host strains) for the production of artemisinic acid, dihydroartemisinic acid or artemisinin. The present disclosure further provides methods of making pharmaceutical products containing artemisinic acid, dihydroartemisinic acid or artemisinin.

The present disclosure provides an engineered microorganism capable of producing malonic acid, malonate, esters of malonic acid, or mixtures thereof. The engineered microorganism includes a malonate-semialdehyde dehydrogenase that is heterologous to a native form of the engineered microorganism and comprises at least 90% sequence identity to SEQ ID NO: 6, wherein the engineered microorganism is capable of producing 3 g/L to 250 g/L of malonic acid, malonate, esters of malonic acid, or mixtures thereof.

The invention provides non-naturally occurring microbial organisms containing butadiene or 2,4-pentadienoate pathways comprising at least one exogenous nucleic acid encoding a butadiene or 2,4-pentadienoate pathway enzyme expressed in a sufficient amount to produce butadiene or 2,4-pentadienoate. The organism can further contain a hydrogen synthesis pathway. The invention additionally provides methods of using such microbial organisms to produce butadiene or 2,4-pentadienoate by culturing a non-naturally occurring microbial organism containing butadiene or 2,4-pentadienoate pathways as described herein under conditions and for a sufficient period of time to produce butadiene or 2,4-pentadienoate. Hydrogen can be produced together with the production of butadiene or 2,4-pentadienoate.

Cell that is genetically modified comprising: a) one or more nucleotide sequence encoding a NAD.sub.+-dependent acetylating acetaldehyde dehydrogenase (E.C. 1.2.1.10); b) one or more nucleotide sequence encoding a acetyl-CoA synthetase (E.C. 6.2.1.1); c) one or more nucleotide sequence encoding a glycerol dehydrogenase (E.C. 1.1.1.6); and d) one or more nucleotide sequence encoding a dihydroxyacetone kinase (E.C. 2.7.1.28 or E.C. 2.7.1.29).

The present disclosure provides compositions and methods for rapid production of chemicals in genetically engineered microorganisms in a large scale. Also provided herein is a high-throughput metabolic engineering platform enabling the rapid optimization of microbial production strains. The platform, which bridges a gap between current in vivo and in vitro bio-production approaches, relies on dynamic minimization of the active metabolic network.